Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel ep...
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
About this item
Full title
Author / Creator
Mims, A , Walker, A R , Huang, X , Sun, J , Wang, H , Santhanam, R , Dorrance, A M , Walker, C , Hoellerbauer, P , Tarighat, S S , Chan, K K , Klisovic, R B , Perrotti, D , Caligiuri, M A , Byrd, J C , Chen, C-S , James Lee, L , Jacob, S , Mrózek, K , Bloomfield, C D , Blum, W , Garzon, R , Schwind, S and Marcucci, G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously, we demonstrated that AML patients with higher
miR
(microRNA)
-29b
expression had better response to the hypomethylating agent decitabine. Therefore, an increase in
...
Alternative Titles
Full title
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3764604
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3764604
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2012.342
